Stockscreener 앱 받기
38.49
0.60%
0.23
Rapport Therapeutics Inc 주식(RAPP)의 최신 뉴스
Rapport Therapeutics (RAPP) director receives 15,200 stock options grant - Stock Titan
[Form 4] Rapport Therapeutics, Inc. Insider Trading Activity - Stock Titan
Rapport Therapeutics (RAPP) director receives 15,200-share stock option grant - Stock Titan
Rapport Therapeutics (RAPP) director granted 15,200 stock options at $35.21 - Stock Titan
Rapport Therapeutics Holds 2026 Annual Shareholder Meeting - TipRanks
Rapport Therapeutics (RAPP) holders elect Class II board, ratify PwC - Stock Titan
Goldman Sachs Group Inc. Buys 579,903 Shares of Rapport Therapeutics, Inc. $RAPP - MarketBeat
Precision Trading with Rapport Therapeutics Inc. (RAPP) Risk Zones - Stock Traders Daily
Rapport Therapeutics (RAPP) Edges Higher Amid Tight Trading RangePut Flow Alert - newsline.com
Is Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative? - Yahoo Finance
Wall Street Firms Raise Rapport Therapeutics Price Targets - sekbernews.id
BTIG and Truist Raise Price Targets for Rapport Therapeutics - HarianBasis.co
BTIG Raises its Price Target on Rapport Therapeutics (RAPP) - Insider Monkey
RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy - TipRanks
5 Stocks That Have the Potential to Rise 1000% - Insider Monkey
Number of shareholders of Rapport Therapeutics, Inc. – NASDAQ:RAPP - TradingView
BTIG Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Citizens reiterates Rapport Therapeutics stock rating on competitor trial data - Investing.com
Citizens reiterates Rapport Therapeutics stock rating on competitor trial data By Investing.com - Investing.com Canada
Rapport Therapeutics (RAPP) Q1 2026 Earnings: Narrower Loss Beats Estimates; Stock Holds Steady - newsline.com
Technical Reactions to RAPP Trends in Macro Strategies - Stock Traders Daily
RAPP Q1 2026 Earnings: Narrower Loss Beats Street Estimates as Pre-Revenue Biotech Advances Pipeline - newsline.com
Rapport Therapeutics (RAPP) Holds Steady as Minor Decline Tests Key Support LevelsKeltner Channel - newsline.com
Third Rock sells 836,136 RAPP shares across April–May 2026 (RAPP) - Stock Titan
Rapport Therapeutics Inc. (RAPP) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock GainProduct Revenue Analysis - Newser
RAPP Should I Buy - Intellectia AI
Rapport Therapeutics (RAPP) Gains 2.7% as Price Approaches Key Resistance LevelValue Factor - Newser
RAPP Maintains Buy Rating -- Price Target Raised to $65.00 by BT - GuruFocus
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Rapport Therapeutics to Participate in the Jefferies Global - GlobeNewswire
Biotech firm Rapport slated for Jefferies and Goldman investor talks - Stock Titan
RAPP Assumes Buy Rating with Price Target Raised to $56.00 by Tr - GuruFocus
Truist Financial Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Rapport Therapeutics (RAPP) Stock Today: Drops -1.71%, Key Support at $32.85 2026-05-19Index Put Call - newsline.com
Rapport Therapeutics Inc (RAPP) - MSN
Truist assumes Rapport Therapeutics stock with buy on epilepsy drug By Investing.com - Investing.com Canada
Truist Financial Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $56 - Moomoo
Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data Upside - TipRanks
Trading the Move, Not the Narrative: (RAPP) Edition - Stock Traders Daily
Will Narrowing Losses And Per Share Improvement Reframe Rapport Therapeutics' (RAPP) Investment Narrative? - simplywall.st
All you need to know about Rapport Therapeutics, Inc. (RAPP) rating upgrade to buy - MSN
Vanguard Group Inc. Acquires 191,219 Shares of Rapport Therapeutics, Inc. $RAPP - MarketBeat
Third Rock Ventures v sells $5.38m in Rapport Therapeutics stock By Investing.com - Investing.com South Africa
Third Rock Ventures v sells $5.38m in Rapport Therapeutics stock - Investing.com
TradingKey - TradingKey
Stifel reiterates Buy on Rapport Therapeutics stock, $56 target By Investing.com - Investing.com Canada
Rapport Therapeutics(RAPP.US) 10% Shareholder Sells US$11.09 Million in Common Stock - Moomoo
Third Rock funds trim Rapport Therapeutics (RAPP) stake under Rule 10b5-1 plan - Stock Titan
Third Rock sells shares of RAPP (NASDAQ: RAPP) under Form 144 - Stock Titan
Swedbank AB Buys Shares of 113,200 Rapport Therapeutics, Inc. $RAPP - MarketBeat
BTIG Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Third Rock sells 697,500 RAPP shares (RAPP) in April–May 2026 - Stock Titan
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A 34% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
RAPP Stock Price and Chart — NASDAQ:RAPP - TradingView
Third Rock Ventures sells 426,005 RAPP shares (NASDAQ: RAPP) - Stock Titan
Rapport Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure Market - TipRanks
(RAPP) Volatility Zones as Tactical Triggers - Stock Traders Daily
1.27%
1.43%
자본화:
|
볼륨(24시간):